logo-loader
viewOrthocell Ltd

Orthocell preparing for launch in the US for its CelGro® bone regeneration product

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott following the news they've completed a submission to the US Food and Drug Administration (FDA) seeking 510(k) clearance for marketing its CelGro® product for dental guided bone and soft tissue regeneration applications.

''We are now starting to build our key opinion leader network in the US so that we're very highly focused, have the right people on board ... and we're moving towards product launch preparation as of today effectively''.

Anderson also updates on the nerve and tendon indications for CelGro® which they're advancing in parallel to the commercialisation of Ortho-ATI® and pipeline products.

Quick facts: Orthocell Ltd

Price: 0.355 AUD

ASX:OCC
Market: ASX
Market Cap: $65.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orthocell publishes positive pre-clinical trial study for CelGro nerve repair

Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment. The results validate claims that the technique can deliver higher quality nerve repair, compared to existing...

on 30/7/19

2 min read